Abstract | PURPOSE:
Radioimmunotherapy (RIT) is a promising treatment approach for B-cell lymphomas. This is our first opportunity to report long-term follow-up data and late toxicities in 29 patients treated with myeloablative doses of iodine-131-anti-CD20 antibody (anti-B1) and autologous stem-cell rescue. PATIENTS AND METHODS: Trace-labeled biodistribution studies first determined the ability to deliver higher absorbed radiation doses to tumor sites than to lung, liver, or kidney at varying amounts of anti-B1 protein (0.35, 1.7, or 7 mg/kg). Twenty-nine patients received therapeutic infusions of single-agent (131)I-anti-B1, given at the protein dose found optimal in the biodistribution study, labeled with amounts of (131)I (280 to 785 mCi [10.4 to 29.0 GBq]) calculated to deliver specific absorbed radiation doses to the normal organs, followed by autologous stem-cell support. RESULTS: Major responses occurred in 25 patients (86%), with 23 complete responses (CRs; 79%). The nonhematopoietic dose-limiting toxicity was reversible cardiopulmonary insufficiency, which occurred in two patients at RIT doses that delivered > or = 27 Gy to the lungs. With a median follow-up time of 42 months, the estimated overall and progression-free survival rates are 68% and 42%, respectively. Currently, 14 of 29 patients remain in unmaintained remissions that range from 27+ to 87+ months after RIT. Late toxicities have been uncommon except for elevated thyroid-stimulating hormone (TSH) levels found in approximately 60% of the subjects. Two patients developed second malignancies, but none have developed myelodysplasia (MDS). CONCLUSION: Myeloablative (131)I-anti-B1 RIT is relatively well tolerated when given with autologous stem-cell support and often results in prolonged remission durations with few late toxicities.
|
Authors | S Y Liu, J F Eary, S H Petersdorf, P J Martin, D G Maloney, F R Appelbaum, D C Matthews, S A Bush, L D Durack, D R Fisher, T A Gooley, I D Bernstein, O W Press |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 16
Issue 10
Pg. 3270-8
(Oct 1998)
ISSN: 0732-183X [Print] United States |
PMID | 9779701
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- Antigens, CD20
- Iodine Radioisotopes
- tositumomab I-131
|
Topics |
- Adult
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antigens, CD20
(immunology)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Humans
- Iodine Radioisotopes
(adverse effects, therapeutic use)
- Lymphoma, B-Cell
(immunology, therapy)
- Male
- Middle Aged
- Radioimmunotherapy
(adverse effects)
- Radiotherapy Dosage
- Recurrence
- Remission Induction
|